title: Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
abstract: The purpose of this meta-analysis was to determine the prognostic value of early response assessment using (18F)fluorodeoxyglucose (FDG)-positron emission thermography (PET) in patients with advanced non-small cell lung cancer (NSCLC) treated with tyrosine-kinase inhibitors (TKIs). MEDLINE, PubMed, Cochrane, EMBASE, and Google Scholar databases were searched until August 1, 2016 using the keywords non-small cell lung carcinoma, positron-emission tomography, fluorodeoxyglucose, prognosis, disease progression, survival, erlotinib, gefitinib, and afatinib. Inclusion criteria were studies of patients with stage III or IV NSCLC treated with a TKI and had response assessed by FDG-PET. Outcome measures were overall survival (OS) and progression-free survival (PFS). Of the 167 articles identified, 10 studies including 302 patients were included in the analysis. In 8 studies, patients were treated with erlotinib, and in 2 they were treated with gefitinib. The overall analysis revealed that early metabolic response was statistically associated with improved OS (HR=0.54; 95% CI 0.46 to 0.63; p<0.001), and with longer PFS (HR=0.23; 95% CI 0.17 to 0.33; p<0.001). Early response of patients with NSCLC treated with TKIs identified on FDG-PET is associated with improved OS and PFS.
authors.affiliation: Department of Thoracic surgery, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Ma
authors.affiliation: Department of Respiratory Medicine, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, China.
authors.forename: Xiaojing
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Thoracic surgery, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, China.
authors.forename: Jianghong
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Thoracic surgery, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, China.
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Thoracic surgery, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000077716:Afatinib; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D018450:Disease Progression; D018572:Disease-Free Survival; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000737:chemistry; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011799:Quinazolines / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000737:chemistry; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000077716:Afatinib; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib
keywords: Cancer